Hong Kong-based genomic and diagnostic testing company Prenetics agreed to list on the Nasdaq via a merger with SPAC Artisan Acquisition Corp in a transaction that values the company at an enterprise value of USD1.25b with a combined equity value of ~USD1.7b. The deal includes a PIPE and forward purchase agreements of USD120m from Aspex Management, PAG, Lippo Group, Dragonstone Capital and Xen Capital. Read more